financial results

Gerresheimer made a moderate start to 2017, as was anticipated, with a slight reduction in revenues. Read more



Source: AstraZeneca

AstraZeneca has posted its Q4 and 2014 full year revenues. With a small increase of just 1% in full year sales, and a 15% drop in net profit, shares fell today, prompting comment from analysts. Read more


In the first half of 2014, Lonza’s specialty ingredients and pharma & biotech segments both delivered a sound performance despite currency headwinds and are fully on track to deliver the growth targets. Read more

Results driven primarily by the company's cancer medicines, particularly the new breast cancer medicines. Read more